Masakazu Toi

This paper shows BRCA2 loss causes genomic instability through ROS-dependent metabolic collapse, highlighting the role of glutathione metabolism and PARP inhibitors in cell death.

This study develops CTX-439, a CDK12/13 inhibitor, showing anti-tumor effects and resistance mechanisms, and proposes combining it with BCL-2 family inhibitors for cancer treatment.

This study shows that GABA treatment reduces estradiol-stimulated breast cancer cell growth and prevents estradiol-induced breast tumorigenesis in a mouse model.